Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Nishida, Yayoi ^a   Takahashi, Yasuo ^a   Nakayama, Tomohiro ^a   Asai, Satoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin ii receptor blocker (ARB); Calcium channel blocker (CCB); Hematological parameter; Retrospective observational study

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE BESYLATE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CHOLESTEROL; CILNIDIPINE; CREATININE; DIHYDROPYRIDINE; EFONIDIPINE; FELODIPINE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; LOSARTAN POTASSIUM; MANIDIPINE; MEPIRODIPINE; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NISOLDIPINE; NITRENDIPINE; NU LOTAN; OLMESARTAN; POTASSIUM; SODIUM; TELMISARTAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ELECTROLYTE DISTURBANCE; ERYTHROCYTE COUNT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LABORATORY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PROPORTIONAL HAZARDS MODEL; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; ERYTHROCYTE COUNT; HEMATOCRIT; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; HYPERTENSION; JAPAN; MULTIVARIATE ANALYSIS; POTASSIUM; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861078970     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-53     Document Type: Article

References (38)

1. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30-48.
2. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, . CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766. 10.1016/S0140-6736(03)14282-1, 13678868, CHARM Investigators and Committees.
3. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, . ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906. 10.1016/S0140-6736(05)67185-1, 16154016, ASCOT Investigators.
4. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, . Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007, 72:1543-1549. 10.1038/sj.ki.5002623, 17943080, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators.
5. Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag 2009, 5:547-552. 2710386, 19707264.
6. Ersoy A, Kahvecioglu S, Ersoy C, Cift A, Dilek K. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. Transplant Proc 2005, 37:2148-2150. 10.1016/j.transproceed.2005.03.085, 15964363.
7. López V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Martínez D, Hernandez D. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients. Transplant Proc 2010, 42:2883-2885. 10.1016/j.transproceed.2010.07.053, 20970559.
8. Chrysant SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens (Greenwich) 2008, 10:716-722.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187. 10.1097/HJH.0b013e3281fc975a, 17563527.
10. Reboldi G, Gentile G, Angeli F, Verdecchia P. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atheroscler Rep 2011, 13:176-185. 10.1007/s11883-011-0160-9, 21234720.
11. Mogensen CE. Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 1994, 235:297-316. 10.1111/j.1365-2796.1994.tb01080.x, 8151262.
12. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207. 10.1016/S0140-6736(07)60108-1, 17240286.
13. Kitamura N, Takahashi Y, Yamadate S, Asai S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2007, 6:26. 10.1186/1475-2840-6-26, 2098751, 17903269.
14. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, . Candesartan Antihypertensive Survival Evaluation in Japan Trial Group Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008, 51:393-398. 10.1161/HYPERTENSIONAHA.107.098475, 18172059, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.
15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, . VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2231. 10.1016/S0140-6736(04)16451-9, 15207952, VALUE trial group.
16. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006, 48:385-391. 10.1161/01.HYP.0000236119.96301.f2, 16864741.
17. Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 2011, 68:123-129.
18. Austin PC, Chiu M, Ko DT, Goeree R, Tu JV. Propensity Score Matching for Estimating Treatment Effects. Analysis of Observational Health Care Data Using SAS 2010, 51-84. SAS Press, Cary, Faries DE, Leon AC, Haro JM, Obenchain RL.
19. Takahashi Y, Nishida Y, Nakayama T, Asai S. Adverse effect profile of trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol 2011, 10:45. 10.1186/1475-2840-10-45, 3118327, 21605415.
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
21. Flores CA, Ardiles LG, Aros CA, Muñoz CC, Schneider HO, Ramírez JA, Jerez V, Valderrama MG, Mezzano SA. Valsartan-induced hematocrit changes in renal transplant patients. Transplant Proc 2005, 37:1586-1588. 10.1016/j.transproceed.2004.09.014, 15866681.
22. Ersoy A, Dilek K, Usta M, Yavuz M, Güllülü M, Oktay B, Yurtkuran M. Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin Transplant 2002, 16:202-205. 10.1034/j.1399-0012.2002.01127.x, 12010144.
23. Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Eur J Pharmacol 1998, 354:179-187. 10.1016/S0014-2999(98)00451-8, 9754919.
24. Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006, 21:1389-1394. 10.1093/ndt/gfk058, 16431893.
25. Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting. Clin Ther 2011, 33:456-464. 10.1016/j.clinthera.2011.04.011, 21635991.
26. Eriksson JW, Jansson PA, Carlberg B, Hägg A, Kurland L, Svensson MK, Ahlström H, Ström C, Lönn L, Ojbrandt K, Johansson L, Lind L. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) Study. Hypertension 2008, 52:1030-1037. 10.1161/HYPERTENSIONAHA.108.119404, 18981327.
27. Kavgaci H, Sahin A, Onder Ersoz H, Erem C, Ozdemir F. The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Res Clin Pract 2002, 58:19-25. 10.1016/S0168-8227(02)00102-X, 12161053.
28. Munger MA. Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T 2011, 36:22-40. 3046622, 21386934.
29. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006, 3:1. 10.1186/1742-4682-3-1, 1360063, 16403216.
30. Yamana A, Arita M, Furuta M, Shimajiri Y, Sanke T. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res Clin Pract 2008, 82:127-131. 10.1016/j.diabres.2008.07.003, 18692932.
31. Mori Y, Tanaka T, Matsuura K, Yokoyama J, Utsunomiya K. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Adv Ther 2011, 28:698-706. 10.1007/s12325-011-0040-2, 21744143.
32. Sinha N, Mishra TK, Singh T, Gupta N. Effect of iron deficiency anemia on hemoglobin A1c levels. Ann Lab Med 2012, 32:17-22. 10.3343/alm.2012.32.1.17, 3255499, 22259774.
33. Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes 2011, 3:67-73. 10.1111/j.1753-0407.2010.00100.x, 20942846.
34. Nakamura T, Inoue T, Suzuki T, Kawagoe Y, Ueda Y, Koide H, Node K. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res 2008, 31:841-850. 10.1291/hypres.31.841, 18712038.
35. Nieschlag E. Behre HM: Testosterone: action, deficiency, substitution 1998, Springer, Berlin, 2.
36. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 2010, 9:38. 10.1186/1475-2840-9-38, 2933671, 20712859.
37. Nishida Y, Takahashi Y, Nakayama T, Soma M, Asai S. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol 2011, 10:74. 10.1186/1475-2840-10-74, 3163179, 21827713.
38. Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006, 47:21-28.